TUSTIN, Calif., May 14 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, is a vertically integrated specialty pharmaceutical company. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL engages in the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The Company today announced that JPI has donated various pharmaceutical products valued at more than $70,000, to the China Red Cross (Chengdu Branch) to provide medical support to the victims of the recent earthquake located in Shichuan Province, which devastated portions of China.
"Not only did our JPI management make this significant donation valued at more than $70,000, it initiated a special trip to Sichuan to ensure that the drugs reached the proper destinations," said Gary Dreher, CEO of AMDL. "The initiative taken by JPI signals its awareness and enthusiasm for its social responsibility. We do not expect that this earthquake will have any negative impact on sales of JJB and or YYB products, in fact, certain products may experience a higher than normal sales growth rate due to the disaster."
About Jade Pharmaceutical: JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and actual
circumstances, events or results may differ materially from those projected
in such forward-looking statements. The Company cautions readers not to
place undue reliance on any forward-looking statements. The Company does
not undertake, and specifically disclaims any obligation, to update or
revise such statements to reflect new circumstances or unanticipated events
as they occur.
Contact: AMDL, Inc.
Mr. Paul Knopick
AMDL Investor Relations
Direct Line: 949.707.5365
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved